Therapeutics

100 VCs and 9 funds investing in Therapeutics

VCs investing in Therapeutics

Alex Morgan

Partner

88%

Khosla Ventures

Check: No personal check range is published. Khosla's Seed Fund supports science and business-model experiments, historically often with roughly $1M–$2M according to a 2020 firm interview, while its Main Fund covers early through later stages. These are firm-level references, not Alex's authority.

Alex invests where computation, biology, and healthcare converge. His scientific and clinical background supports a systems view of biomarker discovery, therapeutics, diagnostics, personalized medicine, neurotechnology, connected devices, and AI-enabled care. He favors important health outcomes and technologies that can automate expensive or inconsistent processes, increase access, and create reproducible, lower-cost care—not science detached from delivery and economics.

IncubationPre-SeedSeed

Ian Metcalfe

Venture Partner, Therapeutics

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ian Metcalfe invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Sabine Kannegiesser

Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Sabine Kannegiesser invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Rachelle Young

Investor Relations Director

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Rachelle Young as Investor Relations Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Elisa Camorani

Senior Associate ESG and Impact

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Elisa Camorani as Senior Associate ESG and Impact. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Cyril Lesser

Vice President Finance | Funds

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Cyril Lesser as Vice President Finance | Funds. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Benjamin Belot

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Benjamin Belot as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Machteld Groeneveld

Chief Compliance Officer & Legal Affairs

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Machteld Groeneveld as Chief Compliance Officer & Legal Affairs. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Oskar Slotboom

Managing Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Oskar Slotboom as Managing Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Daniela Couto

General Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Daniela Couto as General Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Olga Ziessen

Manager Secretarial Services

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Olga Ziessen as Manager Secretarial Services. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Robbert van de Griendt

Head of Investor Relations

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Robbert van de Griendt as Head of Investor Relations. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Wouter Verhoeven

Venture Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Wouter Verhoeven as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Rianne Ellenbroek

Principal

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Rianne Ellenbroek as Principal. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

John J.P. Kastelein

Senior Advisor

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies John J.P. Kastelein as Senior Advisor. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Patricia Vonk

AML/KYC Manager

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Patricia Vonk as AML/KYC Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Jennifer Fritzsche

Vice President Finance

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Jennifer Fritzsche as Vice President Finance. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Silva Dezelan

Head of Impact and ESG

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Silva Dezelan as Head of Impact and ESG. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Karen Chan

Associate

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Karen Chan as Associate. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Dragana Dragusin

Executive Assistant

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Dragana Dragusin as Executive Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Elena Ritsou

Venture Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Elena Ritsou as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Maureen Wouters

Paralegal

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Maureen Wouters as Paralegal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedSeries A

Rob de Ree

Venture Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Rob de Ree as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Christina Takke

Managing Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Christina Takke as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Katja Rosenkranz

Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Katja Rosenkranz as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Martin Solleveld

Finance Manager

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Martin Solleveld as Finance Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationEarly StageMid Stage

Mathias Falcenberg

Venture Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Mathias Falcenberg as Venture Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Shelley Margetson

Managing Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Shelley Margetson as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Ward Capoen

Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Ward Capoen as Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Willem Broekaert

Managing Partner

80%

V-Bio Ventures

Check: V-Bio does not publish a standard current startup check-size range on its official site.

The official roster identifies Willem Broekaert as Managing Partner. This profile applies V-Bio Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Turn differentiated European science into therapeutics companies with strong impact potential, using a preferred relationship with VIB and wider academic sourcing.

Company CreationEarly StageMid Stage

Arnoud Dijkstra

Venture Partner

80%

BioGeneration Ventures

Check: BGV does not publish a standard current startup check-size range on its official site.

The official roster identifies Arnoud Dijkstra as Venture Partner. This profile applies BioGeneration Ventures's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Lead early investments and help shape European biotechnology companies addressing serious unmet medical needs.

Company CreationSeedSeries A

Rémi Droller

Managing Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Rémi Droller as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Amanda Gett

Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Amanda Gett as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Alain Horvais

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Alain Horvais as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Thierry Laugel

Managing Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Thierry Laugel as Managing Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Peter Neubeck

Partner Germany, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Peter Neubeck as Partner Germany, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Daniel Parera

Partner Germany, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Daniel Parera as Partner Germany, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Philippe Peltier

Partner, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Philippe Peltier as Partner, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Jean-François Rivassou

Partner, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Jean-François Rivassou as Partner, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Hadrien Bouchez

Partner, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Hadrien Bouchez as Partner, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Laura Achach

Associate, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Laura Achach as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Samantha Zennou

Associate, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Samantha Zennou as Associate, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Florence de Coorebyter

Associate, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Florence de Coorebyter as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Anna Tchorzewska

Associate, Biofund

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Anna Tchorzewska as Associate, Biofund. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Maylis Deschamps

Associate, Growth Opportunities

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Maylis Deschamps as Associate, Growth Opportunities. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Louise-Marie Rakotoarison

Analyst, Diagnostics

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Louise-Marie Rakotoarison as Analyst, Diagnostics. This profile applies Kurma Partners's published strategy and does not infer undisclosed personal signing authority or a narrower individual mandate. Relevant founder fit follows the firm's thesis: Finance European healthcare innovation from company creation through growth using specialist Biofund, Diagnostics and Growth Opportunities strategies.

Company CreationSeedVenture

Muriel Domine

Secretary General, Head of Compliance & Legal

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Muriel Domine as Secretary General, Head of Compliance & Legal. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Cyril Bedran

Financial Director

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Cyril Bedran as Financial Director. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Sonny Guilhem

Senior Financial Controller

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Sonny Guilhem as Senior Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Ornella Gomis

Financial Controller

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Ornella Gomis as Financial Controller. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Steffi Minga

Office Manager

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Steffi Minga as Office Manager. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Fatima Boubnad

Management Assistant

80%

Kurma Partners

Check: Kurma Partners does not publish one standard check-size range across its current specialist strategies.

The official roster identifies Fatima Boubnad as Management Assistant. This is a fund team or operating role; no direct investment mandate or personal signing authority is inferred.

Company CreationSeedVenture

Gaston Matthyssens, PhD

Managing Partner

80%

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Gaston Matthyssens, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Early StageGrowth

Alain Parthoens

Managing Partner

80%

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Alain Parthoens invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Early StageGrowth

Christian Schneider, PhD

Managing Partner

80%

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Christian Schneider, PhD invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Early StageGrowth

Stephane Verdood

Managing Partner

80%

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Stephane Verdood invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Early StageGrowth

Guy Geldhof

Partner

80%

Vesalius Biocapital

Check: Vesalius Biocapital does not publish a standard current check-size range on its official site.

Guy Geldhof invests or supports investments through Vesalius Biocapital's published strategy: Build a concentrated European life-sciences portfolio across therapeutics, diagnostics, medical devices and digital health with active strategic support.

Early StageGrowth

Dr. Rainer Strohmenger

Managing Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Rainer Strohmenger invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Johannes Fischer

Managing Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Johannes Fischer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Varun Gupta

Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Varun Gupta invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Harald Keller

Managing Partner, CFO

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Harald Keller is listed in a Managing Partner, CFO capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Ernst Mannheimer

Managing Partner, Legal Counsel

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Ernst Mannheimer is listed in a Managing Partner, Legal Counsel capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Ileana Lindeman

Venture Partner, Orthopedics, Spine & Surgery

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ileana Lindeman invests or supports investments through NLC Health Ventures's published strategy: Find, build and scale health innovations from universities, hospitals and corporates, investing alongside founders and external investors.

Pre-SeedSeedVenture Building

Dr. Lisa Gartenmann

Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Lisa Gartenmann invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Robert Buschauer

Associate

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Robert Buschauer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Karina Schuster

Office Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Karina Schuster is listed in a Office Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Ulrike Spring

Sustainability Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Ulrike Spring is listed in a Sustainability Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Cornelia Huber

Finance Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Cornelia Huber is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Karin Juen

Finance Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Karin Juen is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Anja Weibel

Finance Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Anja Weibel is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Olena Ionkina

Finance Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Olena Ionkina is listed in a Finance Manager capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Doris Gowik

Project Manager

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Doris Gowik invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Regina Hodits

Venture Advisor

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Regina Hodits is listed in a Venture Advisor capacity at Wellington Partners. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Prof. Dr. Erich Schlick

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Prof. Dr. Erich Schlick invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Ulrich Granzer

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Ulrich Granzer invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Mel Spigelman

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Mel Spigelman invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Wolfgang Baiker

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Wolfgang Baiker invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Stuart Essig, Ph.D.

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Stuart Essig, Ph.D. invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Bo Jesper Hansen

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Bo Jesper Hansen invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Dr. Peter Hirth

Venture Partner

80%

Wellington Partners

Check: €2M-€20M initial investments, as published by Wellington Partners.

Dr. Peter Hirth invests or supports investments through Wellington Partners's published strategy: Back European life-sciences entrepreneurs from early development through growth in therapeutics, medical devices, diagnostics and digital health.

Early StageGrowth

Alain Parthoens

Chief Executive Officer

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Alain Parthoens is listed in a Chief Executive Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Sadashi Suzuki

Japan Representative

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Sadashi Suzuki is listed in a Japan Representative capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Guy Heynen

Chief Medical and Regulatory Officer

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Guy Heynen is listed in a Chief Medical and Regulatory Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Michihiko Wada

Chief Regulatory and Development Officer

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Michihiko Wada is listed in a Chief Regulatory and Development Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Danny Gonnissen

Chief Operating Officer

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Danny Gonnissen is listed in a Chief Operating Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Pierre Detrixhe

Venture Director

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Pierre Detrixhe invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Early StageGrowth

Tomoko Asaoka

Partner

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Tomoko Asaoka invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Early StageGrowth

Dario Padovani

Chief Financial Officer

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Dario Padovani is listed in a Chief Financial Officer capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Daisuke Morishita

Venture Partner

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Daisuke Morishita invests or supports investments through Newton Biocapital's published strategy: Invest in private life-sciences companies in Europe and Japan whose products address important unmet medical needs.

Early StageGrowth

Toko Senna

Assistant to the CEO / Office Manager

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Toko Senna is listed in a Assistant to the CEO / Office Manager capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Ajit Shetty

Chairman of the Board of NBC I and NBC II

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Ajit Shetty is listed in a Chairman of the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Dirk Boogmans

Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Dirk Boogmans is listed in a Vice-Chairman and Chairman of the Audit Committee of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Jean Combalbert

Independent Director

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Jean Combalbert is listed in a Independent Director capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Jean-Claude Deschamps

Chairman Emeritus and Advisor to the Board of NBC I and NBC II

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Jean-Claude Deschamps is listed in a Chairman Emeritus and Advisor to the Board of NBC I and NBC II capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Goro Takeda

Founder

80%

Newton Biocapital

Check: Newton Biocapital does not publish a standard current check-size range on its official site.

Goro Takeda is listed in a Founder capacity at Newton Biocapital. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Early StageGrowth

Bert-Arjan Millenaar

Founder & CEO

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Bert-Arjan Millenaar is listed in a Founder & CEO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Ruben Mikkers

CFO

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Ruben Mikkers is listed in a CFO capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Amalia Stenberg

Head of Legal, Company Secretary

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Amalia Stenberg is listed in a Head of Legal, Company Secretary capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Emke Bus

Head of Investor Relations & Business Development

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Emke Bus is listed in a Head of Investor Relations & Business Development capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Nia Emami-Shahri, PhD

Entrepreneur in Residence

80%

NLC Health Ventures

Check: NLC publishes venture and fund participation routes but not one standard direct-investment check-size range.

Nia Emami-Shahri, PhD is listed in a Entrepreneur in Residence capacity at NLC Health Ventures. The firm does not publish a person-specific investment thesis for this role; the profile preserves the role distinction and uses the firm's mandate only as shared context.

Pre-SeedSeedVenture Building

Funds focused on Therapeutics